Resolutions from the Annual General Meeting in aXichem AB (publ)
The annual general meeting of aXichem AB (publ) was held on 16 June 2023. The annual general meeting made the following main decisions:
to determine the income statement, the balance sheet, the consolidated income statement and the consolidated balance sheet and that the company's results would be balanced in a new account;
to grant discharge of liability for the board members and the managing director;
that in accordance with the nomination committee's proposal, the board members shall be remunerated with three base price amounts each and the chairman of the board with six base price amounts;
in accordance with the nomination committee's proposal, to re-elect Jan Gustavsson, Gunilla Savring, Jørn H. Berthelsen, Torsten Helsing and Edward van den Elsen as board members, and to re-elect Christian Månsson. It was also decided to re-elect Jan Gustavsson as chairman of the board and Mazars AB as auditor;
that the nomination committee before the 2024 annual general meeting shall consist of Peter Ragnarsson (LMK Ventures) and Torsten Helsing (Manakin LTD) and that the nomination committee shall have the option to decide to appoint a third member to the nomination committee, as a representative of the company's other shareholders. Such possible third member must be appointed by the chairman of the board;
to, in accordance with the board's proposal, change the limits of the articles of association for share capital and number of outstanding shares; and
to authorize the board to, at the latest until the time of the next annual general meeting and on one or more occasions and with or without preferential rights for the shareholders, decide on the issue of new shares, convertibles and/or warrants, however, that such issue must not result in the company's share capital exceeding the company's maximum permitted share capital according to the articles of association.
The information was submitted, through the agency of the contact person, for publication on June 16, 2023, at 12:30 CEST.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Västra Hamnen Corporate Finance AB is Certified Adviser. More information is available at www.axichem.com.